Efficacy of mixed protamine zinc recombinant human insulin lispro injection(50R) in 60 patients with type 2 diabetes mellitus

ZHANG Ai-ming; LI Chai-wei

Abstract：Objective: To evaluate the efficacy of mixed protamine zinc recombinant human insulin lispro injection(50R) (lispro mix 50/50, LM 50) in patients with type 2 diabetes mellitus. Methods: Outpatients and inpatients (n = 60) with type 2 diabetes, who were poorly controlled by oral hypoglycemic agents, were enrolled. After advanced behavior period of 10 days with Humulin 70/30, they were randomly divided into two groups, and treated with either LM 50 or Humulin 70/30. At intervals of 3 days, blood glucose spectrum was monitored, and insulin dose was adjusted according to blood glucose. Patients with obesity took metformin additionally but not took other insulin secretion-promoting oral hypoglycemic drugs. After treatment for 12 weeks, a cross-over study was performed, namely the dose regimens were exchanged each other in two groups, with equal insulin amounts and same oral mefformin treatment. At 12 and 24 weeks, the following indicators were observed and compared: fasting blood glucose (FBG), plasma glucose 2 h after breakfast (2h-PBG, early), blood glucose 2 h after dinner (2h-PBG, evening), glycosylated hemoglobin (HbA_(1c)), the incidence of perceived hypoglycemia, the total amount of insulin and other indicator changes. Results: The controls of the overall blood glucose were not significantly different in two groups, that is, levels of HbA_(1c) were similar in two groups. However, the control of postprandial blood glucose and the incidence of hypoglycemia were significantly more effective in LM 50 group than in Humulin 70/30 group. Conclusion : LM 50 is effective in treatment of type 2 diabetes, especially in controlling postprandial blood glucose, and the incidence of hypoglycemia is lower as compared to Humulin 70/30.